PPARA and metabolic dysfunction-associated steatotic liver disease: Pharmaco-therapeutic efforts to treat NAFLD include lipid-altering agents such as statins and nuclear receptor agonists that regulate multiple metabolic processes such as PPAR agonists used against hypertriglyceridemia [32,33].